Efficacy and Safety of FTY720 for Acute Stroke

Inclusion Criteria: * Age 18-80 years * Clinical presentation of spontaneous intracerebral hemorrhage/ischemic stroke * MRI/MRA scan compatible with spontaneous intracerebral hemorrhage/ ischemic stroke * Time to fty720 treatment\< 72 h from symptom onset * Glasgow Coma Score \>6 on initial presentation or improvement to a Glasgow Coma Score \>6 within the time frame for enrollment. * Primary supratentorial ICH of ≥5cc and \<30cc * TOAST: Large-artery atherosclerosis Exclusion Criteria: * Patients who will undergo surgical evacuation of intracerebral hemorrhage * Inability to undergo neuroimaging with Magnetic Resonance * Glasgow Coma Score \< 6. * Baseline modified Rankin Scale score \>1 * Primary intraventricular hemorrhage ICH due to coagulopathy (PT \> 15 s or International Normalized Ratio \> 1.3, Partial Thromboplastin Time \> 36) or trauma * Thrombocytopenia: platelet count \<100 000 * Clinically significant hepatic disease as demonstrated by history, clinical exam (ascites, varices), or laboratory findings (LFTs \>2x normal, coagulopathy as described) * Comorbid conditions likely to complicate therapy including but not limited to the following: a history of New York Heart Association class II, III, or IV Congestive Heart Failure; end-stage acquired immune deficiency syndrome * Pregnancy * Malignancy (history of or active) * Bradyarrhythmia and Atrioventricular Block * Concomitant use with antineoplastic,immunosuppressive or immune modulating therapies * Macular Edema